Pulmonary Atresia Diagnostics and Treatment Market Research Report – Forecast to 2027

Global Pulmonary Atresia Diagnostics and Treatment Market: Type (Intact Ventricular Septum, Ventricular Septum Defect), Diagnosis (Pulse Oximetry, Echocardiogram), Treatment (Medication, Surgery), End-Users (Hospitals, Clinics)–Global Forecast Till 2027

ID: MRFR/Pharma/5025-HCR | | Region: Global | 100 pages

Please note that the assessment period of report has been updated from 2018-2023 to 2020-2027. Cordially fill the sample form for updated data.

Market Scenario


The global pulmonary atresia diagnostics and treatment market is expected to register a significant growth during the forecast period (2018–2023).


Pulmonary atresia is the type of inherited heart defect that a baby is born with. It arises when the pulmonary valve normally located between the right ventricle and the pulmonary artery doesn’t form properly. The valve should have three leaflets which allow the blood to flow forward into the pulmonary artery but prevent it from flowing backward into the right ventricle. In the case of congenital pulmonary atresia patients, the valve either malfunctions or does not form at all. The tissue formed in the place of pulmonary valve does not allow the blood flow into the pulmonary artery. This flaw develops in the first eight weeks of pregnancy and disturbs the flow of blood from the right ventricle to the pulmonary artery leading to the lungs. It can be recognized in a prenatal ultrasound.


The most common symptoms are blue or gray-toned skin, troubled breathing, weakness, sleepiness, and others. Factors such as technological advancements, increasing awareness, lifestyle changes are the major driving factors for the growth of the market. However, unspecified regulatory issues, infection risks connected with surgical procedures, and ambiguous reimbursement policies are the factors limiting the market growth. Additionally, restrains for the market include the high cost of the surgical procedure and the risks involved in the procedures are likely to affect the pulmonary atresia diagnostics and treatment market negatively. 


Segmentation


The global pulmonary atresia diagnostics and treatment market has been segmented on the basis of type, diagnosis, treatment and end users.


On the basis of type, the market has been classified as pulmonary atresia with an intact ventricular septum and pulmonary atresia with ventricular septum defect.


On the basis of diagnosis, the market has been classified as pulse oximetry, electrocardiogram (ECG), echocardiogram (cardiac ultrasound), cardiac MRI and cardiac catheterization.


On the basis of treatment, the market has been classified as medication, cardiac catheterization, surgery. The cardiac catheterization is segmented into radiofrequency ablation and balloon valvotomy, balloon atrial septostomy, and stent placement. The surgery is segmented into right ventricular outflow reconstruction, blalock-taussig shunt, bi-directional glenn procedure, fontan procedure, and heart transplant.


On the basis of end users, the market has been classified as hospitals, clinics, diagnostic centers, specialty clinics, research institutes, and others.


On the basis of region, the market is segmented into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The Americas has been further segmented into North America and South America, with the North American market divided into the US and Canada.


The European pulmonary atresia diagnostics and treatment market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. 


The pulmonary atresia diagnostics and treatment market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The pulmonary atresia diagnostics and treatment market in the Middle East and Africa has been segmented into the Middle East and Africa.


Regional Market Summary


Global Pulmonary Atresia Diagnostics and Treatment Market Share, by Region, 2017 (%)


Pulmonary Atresia Diagnostics and Treatment Market Share


Source: MRFR Analysis


In the pulmonary atresia diagnostics and treatment market, North America is anticipated to account for the largest market share due to the early adoption of advanced medical technologies, continuous development by companies operating into medical devices manufacturing. According to the Centers for Disease Control and Prevention, about 40,000 births are affected by congenital heart defects in the US every year.


The European market is expected to hold the second largest market share. Factors such as a rise in research expenses, advancement of technology, the decline in human health, and the necessity for innovative and effective therapies boost the growth of the market in this region. According to the Centers for Disease Control and Prevention, congenital heart defects are a foremost cause of birth defect associated with infant illness and deaths. The deaths often occur when the infant is less than 28 days old and hence diagnosis of the defect is utmost important.


Whereas the market share in Asia-Pacific region is also anticipated to experience growth in the near future due to access to optimal treatment facilities and growing demand for increasing government initiatives, advanced technology, better adoption rate, and rising healthcare expenditure.


The market in the Middle East & Africa is expected to account for the smallest share of the global pulmonary atresia diagnostics and treatment market due to an underdeveloped healthcare sector, the dearth of technical knowledge, and poor medical facilities.


Key Players


Some of the key players in the global pulmonary atresia diagnostics and treatment market are Kyowa Pharma Chemical Co. Ltd, AZAD partners, Abbott Laboratories, Dickinson and Company, Becton, C. R. Bard, Inc., B. Braun Melsungen AG, Medtronic plc., Teleflex Incorporated, JOHNSON & JOHNSON, Cook Group Incorporated, and Boston Scientific Corporation.


Global Pulmonary Atresia Diagnostics and Treatment Market, by Type



  • Pulmonary atresia with an intact ventricular septum

  • Pulmonary atresia with ventricular septum defect


Global Pulmonary Atresia Diagnostics and Treatment Market, by Diagnosis



  • Pulse oximetry

  • Electrocardiogram (ECG)

  • Echocardiogram (cardiac ultrasound)

  • Cardiac MRI

  • Cardiac catheterization


Global Pulmonary Atresia Diagnostics and Treatment Market, by Treatment



  • Medication

  • Cardiac catheterization

  • Radiofrequency ablation

  • Balloon valvotomy

  • Balloon atrial septostomy

  • Stent placement

  • Surgery

  • Right ventricular outflow reconstruction

  • Blalock-Taussig Shunt

  • Bi-directional Glenn procedure

  • Fontan procedure

  • Heart transplant


Global Pulmonary Atresia Diagnostics and Treatment Market, by End-Users



  • Hospitals

  • Clinics

  • Diagnostic centers

  • Specialty Clinics

  • Research Institutes

  • Others


Global Pulmonary Atresia Diagnostics and Treatment Market, by Region



  • Americas

  • North America

  • US

  • Canada

  • South America

  • Europe

  • Western Europe

  • Germany

  • France

  • Italy

  • Spain

  • UK

  • Rest of Western Europe

  • Eastern Europe

  • Asia-Pacific

  • Japan

  • China

  • India

  • Australia

  • South Korea

  • Rest of Asia-Pacific

  • Middle East & Africa

  • Middle East

  • Africa


Intended Audience



  • Governmental Agency

  • Educational Organizations

  • Medical Device Manufacturers

  • Research Institutes and Academic Centers



  • Market Research and Consulting



Frequently Asked Questions (FAQ) :


Pulmonary atresia is an inherited, congenital heart defect in which the pulmonary valve between the right ventricle and the pulmonary artery doesn’t form or function properly.

Major ways of diagnosing Pulmonary Atresia are ECG, pulse oximetry, cardiac ultrasound, cardiac MRI, and cardiac catheterization.

Growing awareness about inherited diseases is likely to be the major driver for the Pulmonary Atresia Diagnostics and Treatment Market.

North America is anticipated to account for the largest share in the global Pulmonary Atresia Diagnostics and Treatment Market.

Leading players in the market include Abbott, AZAD Partners, and C.R. Bard, among others.

Table of Contents:

Chapter 1. Report Prologue

Chapter 2. Market Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

Chapter 3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary Research

3.4 Market Size Estimation

Chapter 4. Market Dynamics

4.1 Drivers

4.2 Restraints

4.3 Opportunities

4.4 Challenges

4.5 Macroeconomic Indicators

4.6 Technology Trends & Assessment

Chapter 5. Market Factor Analysis

5.1 Porter’s Five Forces Analysis

5.1.1 Bargaining Power of Suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

5.2 Value Chain Analysis

5.3 Investment Feasibility Analysis

5.4 Pricing Analysis

Chapter 6. Global Pulmonary Atresia Diagnostics and Treatment Market, by Type

6.1 Introduction

6.2 Pulmonary atresia with intact ventricular septum

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

6.3 Pulmonary atresia with ventricular septum defect

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

Chapter 7. Global Pulmonary Atresia Diagnostics and Treatment Market, by Diagnosis

7.1 Introduction

7.2 Pulse oximetry

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

7.3 Electrocardiogram (ECG)

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

7.4 Echocardiogram (cardiac ultrasound)

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

7.5 Cardiac MRI

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

7.6 Cardiac catheterization

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

Chapter 8. Global Pulmonary Atresia Diagnostics and Treatment Market, by Treatment

8.1 Introduction

8.2 Medication

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

8.3 Cardiac catheterization

8.3.1 Radiofrequency ablation

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

8.3.2 Balloon valvotomy

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

8.3.3 Balloon atrial septostomy

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

8.3.4 Stent placement

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

8.4 Surgery

8.4.1 Right ventricular outflow reconstruction

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

8.4.2 Blalock-Taussig Shunt

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

8.4.3 Bi-directional Glenn procedure

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

8.4.4 Fontan procedure

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

8.4.5 Heart transplant

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

Chapter 9. Global Pulmonary Atresia Diagnostics and Treatment Market, by End-Users

9.1 Introduction

9.2 Hospitals

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

9.3 Clinics

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

9.4 Diagnostic centers

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

9.5 Specialty Clinics

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

9.6 Research Institutes

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

9.7 Others

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

Chapter 10. Global Pulmonary Atresia Diagnostics and Treatment Market, by Region

10.1 Introduction

10.2 Americas

10.2.1 North America

10.2.1.1 US

10.2.1.2 Canada

10.2.2 South America

10.3 Europe

10.3.1 Western Europe

10.3.1.1 Germany

10.3.1.2 France

10.3.1.3 Italy

10.3.1.4 Spain

10.3.1.5 UK

10.3.1.6 Rest of Western Europe

10.3.2 Eastern Europe

10.4 Asia-Pacific

10.4.1 Japan

10.4.2 China

10.4.3 India

10.4.4 Australia

10.4.5 South Korea

10.4.6 Rest of Asia-Pacific

10.5 Middle East & Africa

10.5.1 Middle East

10.5.2 Africa

Chapter 11. Company Landscape

11.1 Introduction

11.2 Market Share Analysis

11.3 Key Development & Strategies

Chapter 12. Company Profiles

12.1 Kyowa Pharma Chemical Co. Ltd

12.1.1 Company Overview

12.1.2 Type Overview

12.1.3 Financials Overview

12.1.4 Key Developments

12.1.5 SWOT Analysis

12.2 Abbott Laboratories

12.2.1 Company Overview

12.2.2 Type Overview

12.2.3 Financial Overview

12.2.4 Key Developments

10.2.5 SWOT Analysis

12.3 AZAD partners

12.3.1 Company Overview

12.3.2 Type Overview

12.3.3 Financial Overview

12.3.4 Key Development

12.3.5 SWOT Analysis

12.4 Dickinson and Company

12.4.1 Company Overview

12.4.2 Technology/Business Segment Overview

12.4.3 Financial Overview

12.4.4 Key Development

12.4.5 SWOT Analysis

12.5 Becton

12.5.1 Company Overview

12.5.2 Type Overview

12.5.3 Financial overview

12.5.4 Key Developments

12.5.5 SWOT Analysis

12.6 C. R. Bard, Inc.

12.6.1 Company Overview

12.6.2 Type Overview

12.6.3 Financial Overview

12.6.4 Key Developments

12.6.5 SWOT Analysis

12.7 B. Braun Melsungen AG

12.7.1 Overview

12.7.2 Type Overview

12.7.3 Financial Overview

12.7.4 Key Developments

12.7.5 SWOT Analysis

12.8 Medtronic plc.

12.8.1 Overview

12.8.2 Type/ Technology Overview

12.8.3 Financials

12.8.4 Key Developments

12.8.5 SWOT Analysis

12.9 Teleflex Incorporated

12.9.1 Overview

12.9.2 Type Overview

12.9.3 Financials

12.9.4 Key Developments

12.9.5 SWOT Analysis

12.10 JOHNSON & JOHNSON

12.10.1 Overview

12.10.2 Type Overview

12.10.3 Financials

12.10.4 Key Developments

12.10.5 SWOT Analysis

12.11 Cook Group Incorporated

12.11.1 Overview

12.11.2 Type Overview

12.11.3 Financials

12.11.4 Key Developments

12.11.5 SWOT Analysis

12.12 Boston Scientific Corporation

12.12.1 Overview

12.12.2 Type Overview

12.12.3 Financials

12.12.4 Key Developments

12.12.5 SWOT Analysis

Chapter 13 MRFR Conclusion

13.1 Key Findings

13.1.1 From CEO’s Viewpoint

13.1.2 Unmet Needs of the Market

13.2 Key Companies to Watch

13.3 Predictions for the Biosurgery Industry

Chapter 14. Appendix

LIST OF TABLES

Table 1 Global Pulmonary Atresia Diagnostics and Treatment Market Synopsis, 2020–2027

Table 2 Global Pulmonary Atresia Diagnostics and Treatment Market Estimates and Forecast, 2020–2027 (USD Million)

Table 3 Global Pulmonary Atresia Diagnostics and Treatment Market, by Region, 2020–2027 (USD Million)

Table 4 Global Pulmonary Atresia Diagnostics and Treatment Market, by Type, 2020–2027 (USD Million)

Table 5 Global Pulmonary Atresia Diagnostics and Treatment Market, by Diagnosis, 2020–2027 (USD Million)

Table 6 Global Pulmonary Atresia Diagnostics and Treatment Market, by Treatment, 2020–2027 (USD Million)

Table 7 Global Pulmonary Atresia Diagnostics and Treatment Market, by End-users, 2020–2027 (USD Million)

Table 8 North America: Pulmonary Atresia Diagnostics and Treatment Market, by Type, 2020–2027 (USD

Million)

Table 9 North America: Pulmonary Atresia Diagnostics and Treatment Market, by Diagnosis, 2020–2027 (USD Million)

Table 10 North America: Pulmonary Atresia Diagnostics and Treatment Market, by Treatment, 2020–2027 (USD Million)

Table 11 North America: Pulmonary Atresia Diagnostics and Treatment Market, by End-users, 2020–2027 (USD Million)

Table 12 US: Pulmonary Atresia Diagnostics and Treatment Market, by Type, 2020–2027 (USD Million)

Table 13 US: Pulmonary Atresia Diagnostics and Treatment Market, by Diagnosis, 2020–2027 (USD Million)

Table 14 US: Pulmonary Atresia Diagnostics and Treatment Market, by Treatment, 2020–2027 (USD Million)

Table 15 US: Pulmonary Atresia Diagnostics and Treatment Market, by End-users, 2020–2027 (USD Million)

Table 16 Canada: Pulmonary Atresia Diagnostics and Treatment Market, by Type, 2020–2027 (USD Million)

Table 17 Canada Pulmonary Atresia Diagnostics and Treatment Market, by Diagnosis, 2020–2027 (USD Million)

Table 18 Canada: Pulmonary Atresia Diagnostics and Treatment Market, by Treatment, 2020–2027 (USD Million)

Table 19 Canada: Pulmonary Atresia Diagnostics and Treatment Market, by End-users, 2020–2027 (USD Million)

Table 20 South America: Pulmonary Atresia Diagnostics and Treatment Market, by Type, 2020–2027 (USD Million)

Table 21 South America: Pulmonary Atresia Diagnostics and Treatment Market, by Diagnosis, 2020–2027 (USD Million)

Table 22 South America: Pulmonary Atresia Diagnostics and Treatment Market, by Treatment, 2020–2027 (USD Million)

Table 23 South America: Pulmonary Atresia Diagnostics and Treatment Market, by End-users, 2020–2027 (USD Million)

Table 24 Europe: Pulmonary Atresia Diagnostics and Treatment Market, by Type, 2020–2027 (USD Million)

Table 25 Europe Pulmonary Atresia Diagnostics and Treatment Market, by Diagnosis, 2020–2027 (USD Million)

Table 26 Europe: Pulmonary Atresia Diagnostics and Treatment Market, by Treatment, 2020–2027 (USD Million)

Table 27 Europe: Pulmonary Atresia Diagnostics and Treatment Market, by End-users, 2020–2027 (USD Million)

Table 28 Western Europe: Pulmonary Atresia Diagnostics and Treatment Market, by Type, 2020–2027 (USD Million)

Table 29 Western Europe: Pulmonary Atresia Diagnostics and Treatment Market, by Diagnosis, 2020–2027 (USD Million)

Table 30 Western Europe: Pulmonary Atresia Diagnostics and Treatment Market, by Treatment, 2020–2027 (USD Million)

Table 31 Western Europe: Pulmonary Atresia Diagnostics and Treatment Market, by End-users, 2020–2027 (USD Million)

Table 32 Eastern Europe: Pulmonary Atresia Diagnostics and Treatment Market, by Type, 2020–2027 (USD Million)

Table 33 Eastern Europe: Pulmonary Atresia Diagnostics and Treatment Market, by Diagnosis, 2020–2027 (USD Million)

Table 34 Eastern Europe: Pulmonary Atresia Diagnostics and Treatment Market, by Treatment, 2020–2027 (USD Million)

Table 35 Eastern Europe: Pulmonary Atresia Diagnostics and Treatment Market, by End-users, 2020–2027 (USD Million)

Table 36 Asia-Pacific: Pulmonary Atresia Diagnostics and Treatment Market, by Type, 2020–2027 (USD Million)

Table 37 Asia-Pacific: Pulmonary Atresia Diagnostics and Treatment Market, by Diagnosis, 2020–2027 (USD Million)

Table 38 Asia-Pacific: Pulmonary Atresia Diagnostics and Treatment Market, by Treatment, 2020–2027 (USD Million)

Table 39 Asia-Pacific: Pulmonary Atresia Diagnostics and Treatment Market, by End-users, 2020–2027 (USD Million)

Table 40 Middle East & Africa: Pulmonary Atresia Diagnostics and Treatment Market, by Type, 2020–2027 (USD Million)

Table 41 Middle East & Africa: Pulmonary Atresia Diagnostics and Treatment Market, by Diagnosis, 2020–2027 (USD Million)

Table 42 Middle East & Africa: Pulmonary Atresia Diagnostics and Treatment Market, by Treatment, 2020–2027 (USD Million)

Table 43 Middle East & Africa: Pulmonary Atresia Diagnostics and Treatment Market, by End-users, 2020–2027 (USD Million)

LIST OF FIGURES

Figure 1 Research Process

Figure 2 Segmentation for the Global Pulmonary Atresia Diagnostics and Treatment Market

Figure 3 Segmentation Market Dynamics for the Global Pulmonary Atresia Diagnostics and Treatment Market

Figure 4 Global Pulmonary Atresia Diagnostics and Treatment Market Share, by Type, 2020

Figure 5 Global Pulmonary Atresia Diagnostics and Treatment Market, by End-users, 2020–2027 (USD Million)

Figure 6 Global Pulmonary Atresia Diagnostics and Treatment Market Share, by Region, 2020

Figure 7 North America: Pulmonary Atresia Diagnostics and Treatment Market Share, by Country, 2020

Figure 8 Europe: Pulmonary Atresia Diagnostics and Treatment Market Share, by Country, 2020

Figure 9 Asia-Pacific: Pulmonary Atresia Diagnostics and Treatment Market Share, by Country, 2020

Figure 10 Middle East & Africa: Pulmonary Atresia Diagnostics and Treatment Market Share, by Country, 2020

Figure 11 Global Pulmonary Atresia Diagnostics and Treatment Market: Company Share Analysis, 2020 (%)

Figure 12 Kyowa Pharma Chemical Co. Ltd: Key Financials

Figure 13 Kyowa Pharma Chemical Co. Ltd: Segmental Revenue

Figure 14 Kyowa Pharma Chemical Co. Ltd: Geographical Revenue

Figure 15 Abbott Laboratories: Key Financials

Figure 16 Abbott Laboratories: Segmental Revenue

Figure 17 Abbott Laboratories: Geographical Revenue

Figure 18 AZAD partners: Key Financials

Figure 19 AZAD partners: Segmental Revenue

Figure 20 AZAD partners: Geographical Revenue

Figure 21 Dickinson and Company: Key Financials

Figure 22 Dickinson and Company: Segmental Revenue

Figure 23 Dickinson and Company: Geographical Revenue

Figure 24 Becton: Key Financials

Figure 25 Becton: Segmental Revenue

Figure 26 Becton: Geographical Revenue

Figure 27 C. R. Bard, Inc.: Key Financials

Figure 28 C. R. Bard, Inc.: Segmental Revenue

Figure 29 C. R. Bard, Inc.: Geographical Revenue

Figure 30 B. Braun Melsungen AG: Key Financials

Figure 31 B. Braun Melsungen AG: Segmental Revenue

Figure 32 B. Braun Melsungen AG: Geographical Revenue

Figure 33 Medtronic plc.: Key Financials

Figure 34 Medtronic plc.: Segmental Revenue

Figure 35 Medtronic plc.: Geographical Revenue

Figure 36 Teleflex Incorporated: Key Financials

Figure 37 Teleflex Incorporated: Segmental Revenue

Figure 38 Teleflex Incorporated: Geographical Revenue

Figure 39 JOHNSON & JOHNSON: Key Financials

Figure 40 JOHNSON & JOHNSON: Segmental Revenue

Figure 41 JOHNSON & JOHNSON: Geographical Revenue

Figure 42 Cook Group Incorporated: Key Financials

Figure 43 Cook Group Incorporated: Segmental Revenue

Figure 44 Cook Group Incorporated: Geographical Revenue

Figure 45 Boston Scientific Corporation: Key Financials

Figure 46 Boston Scientific Corporation: Segmental Revenue

Figure 47 Boston Scientific Corporation: Geographical Revenue